Home Alzheimer’s Disease Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL

Interim Phase II ZUMA-5 Results Show Promise for Axi-Cel in R/R iNHL

Results from an interim analysis of the phase II ZUMA-5 study showed that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.1

The results, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting, indicate that axi-cel may be a promising approach for treating this patient population according to the investigators. 

“Advanced-stage indolent B-cell non-Hodgkin lymphomas are largely incurable with conventional therapies, with many patients experiencing multiple relapses over the natural history of their disease and remission shortening with subsequent therapies,” Caron A. Jacobson, MD, of the Dana-Farber…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

please help us fundraise (501c3 non-profit) : braincancer

I work with OurBrainBank, a start-up non-profit dedicated to moving glioblastoma from terminal to treatable, powered by patients.We're a registered 501c3 non-profit in the...

Cancer and Mental Health Re-post : braincancer

Hello!I would like to thank everyone who participated in my survey these past few months! I received a tremendous response and I truly, truly...

Recent Comments